

Patterns of social determinants of health associated with drug use among women living with HIV in Canada: a latent class analysis

Mostafa Shokoohi¹ , Greta R. Bauer¹, Angela Kaida², Carmen H. Logie^{3,4}, Ashley Lacombe-Duncan⁵, M.-J. Milloy^{6,7} , Elisa Lloyd-Smith⁸, Allison Carter^{2,9}, Mona Loutfy^{4,10,11} & on behalf of the CHIWOS Research Team*

ABSTRACT

Background and Aims Identifying typologies of social determinants of health (SDoH) vulnerability influencing drug use practices among women living with HIV (WLWH) can help to address associated harms. This research aimed to explore the association of SDoH clusters with drug use among WLWH. **Design** Latent class analysis (LCA) was used to identify the distinct clusters of SDoH. Inverse probability weighting (IPW) was employed to account for confounding and potential selection bias. Associations were analyzed using generalized linear model with log link and Poisson distribution, and then weighted risk ratio (RR) and 95% confidence intervals (CI) were reported. **Setting and Participants** Data from 1422 WLWH recruited at time-point 1 of the Canadian HIV Women's Sexual and Reproductive Health Cohort Study (CHIWOS, 2013–15), with 1252 participants at 18 months follow-up (time-point 2). **Measurements** Drug use was defined as use of illicit/non-prescribed opioids/stimulants in the past 6 months. SDoH indicators included: race discrimination, gender discrimination, HIV stigma, social support, access to care, food security, income level, employment status, education, housing status and histories of recent sex work and incarceration. **Findings** LCA identified four SDoH classes: no/least SDoH adversities (6.6%), discrimination/stigma (17.7%), economic hardship (30.8%) and most SDoH adversities (45.0%). Drug use was reported by 17.5% and 17.2% at time-points 1 and 2, respectively. WLWH with no/least SDoH adversities were less likely to report drug use than those in economic hardship class (weighted RR = 0.13; 95% CIs = 0.03, 0.63), discrimination/stigma class (weighted RR = 0.15; 95% CIs = 0.03, 0.78), and most SDoH adversities class (weighted RR = 0.13; 95% CIs = 0.03, 0.58). **Conclusions** Social determinants of health vulnerabilities are associated with greater likelihood of drug use, underscoring the significance of addressing interlinked social determinants and drug use through the course of HIV care and treatment.

Keywords Canada, CHIWOS, drug use, HIV, social determinants, women.

Correspondence to: Mostafa Shokoohi, The University of Western Ontario, Department of Epidemiology and Biostatistics, K201 Kresge Building, London, Ontario, N6A 5C1, Canada. E-mail: mshokooh@uwo.ca

Submitted 10 September 2018; initial review completed 13 December 2018; final version accepted 21 January 2019

Please see list of authors' affiliations and the CHIWOS Research Team details at the end of the paper.

INTRODUCTION

Illicit drug use, particularly opioids and stimulants, is common among people living with HIV (PLWH). For example, 10, 24 and 39% of PLWH in a US study reported heroin, amphetamines and cocaine use, respectively, by any administration route [1]. Although data on the prevalence of drug use among women living with HIV (WLWH) are limited, 28.6% of WLWH reported recent crack cocaine use, with 3.2% as persistent users [2]. In Canada, available evidence showed that 25.0 and 11.3% of WLWH reported recent crack cocaine and heroin use (by any route), respectively [3].

Illicit drug use remains one of the most important factors influencing engagement in the HIV care cascade

among individuals with HIV [1,4–6]. Much evidence has documented poorer HIV treatment outcomes among people who use drugs, particularly among WLWH [5–11]. For example, greater suboptimal combination antiretroviral therapy (cART) adherence was documented among WLWH who reported a history of drug use than among women who did not, or among men regardless of drug use [7]. Drug use also predicts increased risk of disease progression, HIV transmission and mortality [1,2,10], and continues to complicate HIV care and treatment efforts among PLWH [12,13]. Although active drug use has been shown to complicate the clinical management of individuals with HIV and common comorbidities such as hepatitis C, increasing evidence documents how marginalization and criminalization of people who use/inject drugs

interferes with access and adherence to HIV medications [14]. Particular attention, therefore, needs to be given to such drug use practice throughout the course of HIV care and treatment among WLWH.

Although some determinants of illicit drug use are well documented (e.g. demographics, cognitive, behavioral) [15], few studies have explored the role of the social determinants of health (SDoH). The SDoH are the conditions (e.g. economic and social marginalization and various forms of discrimination) in which people are born, work, live and age, and the wider set of forces shaping the conditions of daily life that greatly contribute to health inequalities [16]. Greater adversities regarding these living conditions can lead to high levels of physiological and psychological stresses arising from coping with stressors [16]. For PLWH, HIV-related stigma in intersection with other social determinants (e.g. race and gender discrimination) [17] can result in coping behaviors such as illicit drug use [18] to help contend with worries and stresses [19] which can, in turn, increase vulnerabilities to HIV-related health outcomes [18,20–22].

Notably, multiple dimensions of SDoH tend to co-occur, and may cluster together into common combinations. Such concomitant determinants have been consistently treated as independent when studied in association with drug use. For example, previous studies have assessed the separate association of HIV stigma [23], food insecurity [24], unemployment [25] and low social support [26] with drug use. However, there are limited data examining how clustering of these determinants is related to drug use. Such evidence is essential for developing HIV care and treatment programs to address potentially modifiable adversities and reduce their impacts on the lives of WLWH. Drawing on the Canadian HIV Women's Sexual and Reproductive Health Cohort Study (CHIWOS) [27], we conducted a latent class analysis (LCA) to uncover underlying clusters of SDoH. LCA as a data reduction strategy classifies individuals into mutually exclusive and exhaustive latent classes using multiple categorical observed variables [28]. LCA has been a useful technique for identifying population subgroups in different disciplines (e.g. substance-using women at risk for HIV [29]). We then applied inverse probability weighting to address confounding and selection bias in examining the association of the clusters of SDoH with drug use.

METHODS

Study sample

We used data from CHIWOS (www.chiwos.ca), a community-based cohort study. As previously described [27], CHIWOS is a large cohort of WLWH (≥ 16 years; trans inclusive) residing in the Canadian provinces of British Columbia (BC), Ontario and Quebec. WLWH ($n = 1422$)

were interviewed during 2013–15 (time-point 1) and after ~ 18 months (time-point 2; $n = 1252$). We considered 170 participants (11.9%) lacking time-point 2 data as censored. Participants were recruited through peers, HIV clinics, AIDS service or community-based organizations, word of mouth and other methods [30]. Trained peer research associates (PRAs) administered the survey through in-person interviews at clinics, community sites or participants' homes or via phone/Skype. Informed consent was obtained from all participants prior to the interview, consistent with the ethics protocol approved by Simon Fraser University, University of British Columbia/Providence Health, Women's College Hospital and McGill University Health Centre.

Drug use

Recent drug use was defined as last 3 months at the first time-point and last 6 months at the second time-point, and included use of opioids (heroin, speedballs, Dilaudid, non-prescribed methadone, OxyContin/Oxycodone, morphine, Talwin & Ritalin) or stimulants [cocaine, crack, crystal methamphetamine, amphetamine, 3,4-methylenedioxymethamphetamine (MDA)]. The regular (daily or at least once/week) or episodic (less than once/week) use of these drugs was ascertained among those who reported any use. Due to small proportions in the episodic use category (i.e. $\sim 1\%$), a binary outcome at time-point 2 was created: use of any versus no drugs.

SDoH indicators

A set of potentially modifiable SDoH that have the potential to co-occur among WLWH were examined at time-point 1, including: racial discrimination, gender discrimination, enacted HIV stigma, perceived social support, barriers to access to care, food security, housing status, income level, employment status, education, recent sex work involvement and recent incarceration. Included SDoH indicators: (a) were measured at the first survey time-point, (b) are potentially modifiable, (c) were currently or recently experienced and (d) align with the Canadian list of SDoH [19] (HIV-related stigma being an exception specific to PLWH). Selection of SDoH was limited to current or recent conditions to avoid the potential for collider stratification bias [31] that could be introduced in a selected (HIV-positive) sample by studying earlier social determinants that may have affected HIV status.

Racial discrimination was measured with the eight-item Everyday Discrimination Scale (current study $\alpha = 0.96$) [32]. In line with operationalization used in the prior research [33], WLWH who reported discriminatory experiences due to their race (e.g. treated with less courtesy, respect) sometimes, frequently or almost every

day were considered as having experienced racial discrimination. The same scale (with the same definition) focusing on discriminatory mistreatments due to gender was used to measure gender discrimination ($\alpha = 0.94$). Enacted HIV stigma was measured using three items of Wright's abridged 10-item version of Berger's HIV Stigma Scale ($\alpha = 0.85$), measuring the extent to which WLWH experienced enacted/personalized stigma towards PLWH [34]. Experience of HIV-related stigma was defined if WLWH reported any HIV-related discriminatory events with strongly agree/agree response options (i.e. been hurt by people's reaction, stopped socializing or lost friends). Social support was examined by the four-item Medical Outcome Study: Social Support Survey [35], measuring emotional-informational, tangible, affectionate and positive social interaction supports ($\alpha = 0.85$). The overall mean score ranged from 1 to 5, with > 2 indicating poor social support availability [36]. Difficulties in access to care was assessed using the 12-item Barriers to Access to Care Scale [37], measuring barriers experienced due to geography/distance, medical and psychological service, community stigma and personal resource ($\alpha = 0.93$). The overall mean severity scores ranged from 1 to 4, with ≥ 2 signifying severe/significant barriers [21]. Past-year experiences of food security were examined by three items: fears of running out of food; experiences of running out of food; and unaffordability of balanced meals, yielding an overall score ranging from 1 to 6, with > 1 indicating food insecurity [38]. Income level was defined as low if participants reported having a yearly household income level $< \$20\,000$. Current employment status was categorized as unemployed (no income or income only from non-employment sources such as unemployment/welfare, dividends and interest or pension) versus employed (any paid job). Current education level was dichotomized as below high school versus completed high school or more. Current housing status was also measured. Participants who reported residing in places such as a self-contained room, transition house, halfway house, safe house or outdoors were considered as unstable housing. Past 6 months sex work involvement was also included, and defined as having been provided with money, drug, shelter, food, etc. in exchange for sex. Finally, any past year experience of incarceration was included as a structural-level determinant indicating social exclusion.

Covariates

The following covariates were hypothesized to be associated with either both SDoH clusters and drug use or only drug use: age (continuous); ethnoracial groups (white/Caucasian, African/Caribbean/black, Indigenous, others); province (BC, Ontario, Quebec); city size (large,

others); sexual orientation (heterosexual, LGBTQ); relationship status (married/common-law/relationship, others); years living with HIV (< 6 years, 6–14 years, > 14 years); cART status [optimal ($\geq 95\%$ adherence), suboptimal ($< 95\%$ adherence), not engaged in HIV treatment]; ever diagnosed with a mental health condition; resilience (10-item Resilience Scale) [39]; any history of childhood sexual/physical violence; any experience of adulthood sexual/physical/verbal/action-limited violence; having been under the care of Child Protection Services or in foster care; and alcohol use [abstainers/low, moderate (one to seven drinks/week), heavy (> 7 drinks/week)]. Drug use history before or at time-point 1 was also included to account for confounding by outcome history [40]. Missing values of covariates under the assumption of missing at random were singly imputed to reduce the loss of statistical power when computing inverse probability weights (IPW) [41].

LCA

We used LCA to identify clusters of SDoH indicators. Under the assumption that latent classes are independent, given the observed indicators, LCA aims to identify distinct groups of individuals with similar patterns within an unobserved categorical variable [28]. LCA was started with a two-class model and systematically increased to more classes (Supporting information, Table S1). LCA provides both class membership probabilities and item-response probabilities condition on class membership to help to interpret the final identified class (Table 1). The expectation-maximization (EM) algorithm with 5000 iterations was employed to identify the best model fit [42]. The selection of the best LCA model was informed by using goodness-of-fit indices, supporting statistics and interpretability of class memberships. The following fit statistics were reported: log-likelihood, Akaike's information criterion (AIC), Bayesian information criterion (BIC) and sample-size-adjusted BIC (aBIC), and consistent AIC (CAIC) [43–45]. Lower values of these criteria indicate better fit and parsimony. Two supporting statistics were also reported: entropy as a measure of classification accuracy, with values approaching to 1 indicating better class separation [46], and the percentage of seeds associated with the fitting models, with values close to 100% indicating they were unlikely to have hit the local maxima. For each model, the log-likelihood was replicated with 1000 random starting values to avoid local maxima. Under the assumption of missing at random, LCA accounted for missing values of the SDoH indicators using the full information maximum likelihood estimation. LCA was conducted using SAS PROC LCA procedure [47].

Table 1 Class membership probabilities and item-response probabilities of Social Determinants of Health (SDoH) from the latent class analysis (LCA) among women living with HIV—CHIWOS (N = 1422).

SDoH measures		None/least SDoH (n = 94; 6.6%) ^a	Discrimination and stigma (n = 256; 18.0%)	Economic hardship (n = 430; 30.2%)	Most SDoH adversities (n = 642; 45.2%)
Race discrimination (708/1408; 50.3%) ^b	No	0.00	0.40 ^c	0.91	0.18
	Yes	0.00	0.60	0.09	0.82
	None ^d	1.00	0.00	0.00	0.00
Gender discrimination (818/1415; 57.1%)	No	0.00	0.33	0.91	0.04
	Yes	0.00	0.67	0.09	0.96
	None	1.00	0.00	0.00	0.00
Enacted HIV stigma (1004/1398; 71.8%)	No	0.00	0.22	0.40	0.17
	Yes	0.00	0.78	0.60	0.83
	None	1.00	0.00	0.00	0.00
Low social support (722/1367; 52.8%)	No	0.00	0.51	0.51	0.37
	Yes	0.00	0.49	0.49	0.63
	None	1.00	0.00	0.00	0.00
High barriers to access to care (725/1371; 52.8%)	No	0.00	0.43	0.55	0.36
	Yes	0.00	0.57	0.45	0.64
	None	1.00	0.00	0.00	0.00
Food insecurity (907/1416; 64.1%)	No	0.00	0.63	0.31	0.18
	Yes	0.00	0.37	0.69	0.82
	None	1.00	0.00	0.00	0.00
Low income (901/1379; 65.3%)	No	0.00	0.90	0.21	0.11
	Yes	0.00	0.10	0.79	0.89
	None	1.00	0.00	0.00	0.00
Unemployment (1098/1412; 77.8%)	No	0.00	0.67	0.09	0.02
	Yes	0.00	0.33	0.91	0.98
	None	1.00	0.00	0.00	0.00
Low education (227/1415; 16.0%)	No	0.00	1.00	0.83	0.75
	Yes	0.00	0.00	0.17	0.25
	None	1.00	0.00	0.00	0.00
Unstably housed (152/1422; 10.7%)	No	0.00	0.99	0.90	0.83
	Yes	0.00	0.01	0.10	0.17
	None	1.00	0.00	0.00	0.00
Recent sex work practice (82/1307; 6.3%)	No	0.00	0.99	0.95	0.90
	Yes	0.00	0.01	0.05	0.10
	None	1.00	0.00	0.00	0.00
Recent incarceration (92/1419; 6.5%)	No	0.00	1.00	0.96	0.88
	Yes	0.00	0.00	0.04	0.12
	None	1.00	0.00	0.00	0.00

^aClass membership probabilities; ^b(n/N; %) indicating the prevalence of the SDoH indicators under the study; ^citem-response probabilities, indicating the probability of experiencing a SDoH indicator for each identified latent class; ^dwe categorized each SDoH measure into three categories: no: indicating either did not have/experience this determinant, yes: indicating either living/experiencing this determinant, None: indicating either did not experience any of these 12 determinants or experienced only one (i.e. least). Item response probabilities of 'Yes' category ≥ 0.50 are shown in bold type, and item response probabilities of 'None' category with 100% are underlined. The 'None' category was added to produce a distinct class named 'None/least SDoH adversities' in order to ease interpretation of the latent classes and reduce LCA model complexity. CHIWOS = Canadian HIV Women's Sexual and Reproductive Health Cohort Study.

Models and estimations

We used inverse probability weights (IPW) [48,49] to account for confounding due to the presence of potentially imbalanced covariates across the SDoH clusters, and inverse probability censoring weights (IPCW) to account for prospective selection bias due to potentially non-random loss to follow-up/censoring (Supporting information, Table S2). The product of these two weights yielded the final stabilized weights (Supporting information, Table S3), producing a pseudo-population in which the

independent variable and covariates are unassociated (Supporting information, Table S4) [48]. In fitting models through IPW, we assumed correct specification of IPW models, conditional exchangeability, consistency and positivity [50].

Control of confounding using IPW

SDoH clusters were modeled using a multinomial logistic regression to estimate stabilized weights: the numerator was computed as the marginal probability of the SDoH

clusters divided by the denominator, which was computed as the probability that a participant was assigned to an SDoH cluster given the covariates and opioid/stimulant use history. These models were all performed among participants without censored information in time-point 2.

Control of selection bias using IPCW

Additionally, to account for any potential selection bias due to differential loss-to-follow-up at time-point 2, we estimated IPCW using logistic regression models: numerator was defined as the probability of not being censored given SDoH and denominator was computed as the probability of not being censored given SDoH, covariates and opioid/stimulant use history [48].

Association of SDoH clusters with drug use

The association between SDoH clusters and any opioid/stimulant use was examined using generalized linear models with log link and Poisson distribution; crude and weighted risk ratios (RRs) and 95% confidence intervals (CIs) were reported. Further adjustment was made for imbalanced covariates after applying the IPW. These analyses were conducted using Stata version 15.

Sensitivity analysis

We reported E-value to evaluate the extent to which residual (unmeasured) confounding might explain away the observed associations, and computed as: $E = RR^* + \sqrt{RR^* \times RR^* - 1}$, where $RR^* = 1/RR$ for $RR < 1$ [51]. E-value is a representation of the minimum strength of association that an unmeasured confounder would need to have with SDoH clusters and drug use to nullify the observed associations.

RESULTS

SDoH classes

Prevalences for individual social determinants ranged from 6.3% ($n = 82/1307$) and 6.5% ($n = 92/1419$) for recent sex work involvement and incarceration to 71.8% ($n = 1004/1398$) and 77.8% ($n = 1098/1412$) for enacted HIV stigma and unemployment, respectively (Table 1). After considering LCA fit statistics and model interpretability, the four-class model was determined as the optimal number of classes (Supporting information, Table S1). These four classes included WLWH with either none or least SDoH adversities (class 1 labeled as no/least SDoH adversities: $n = 94$ [6.6%]); WLWH who predominantly reported experiencing race and gender discrimination along with HIV-related stigma and barriers in access to care, but without economic hardship indicators [class 2 labeled as discrimination/stigma: $n = 256$ (18.0%); WLWH who

mainly reported food insecurity, low household income and unemployment, accompanied with HIV-related stigma [class 3 labeled as economic hardship: $n = 430$ (30.2%); and WLWH who experienced gender and race discrimination, HIV-related stigma, low social support, access to care difficulties, food insecurity, low income and unemployment [class 4 labeled as most SDoH adversities: $n = 642$ (45.2%)].

Participants' characteristics

WLWH were an average of 42.8 [standard deviation (SD) = 10.6] years of age, with 584 (41.1%) members of the white ethnoracial group, 1237 (87.3%) heterosexual, 689 (48.5%) single, 552 (40.2%) living with HIV for 6–14 years, 863 (70.0%) self-reporting optimal cART adherence; 819 (62.7%) and 1057 (80.4%) reported exposure to violence as children and adults, respectively, 573 (40.7%) reported a mental health diagnosis and 140 (10.1%) were heavy alcohol users. The distributions of these covariates across the SDoH clusters are presented in Table 2.

SDoH clusters and drug use

Overall, opioid/stimulant use at time-points 1 and 2 were reported, respectively, by 244 (17.5%) and 212 (17.2%). Drug use at time-point 2 was reported by 143 (26.4%) among WLWH with most SDoH adversities, with 53 (14.1%), 13 (5.6%) and three (3.5%) for economic hardship, discrimination/stigma and no/least SDoH classes, respectively (Fig. 1). The crude regression analysis demonstrated that WLWH in the no/least SDoH adversities, discrimination/stigma and economic hardship classes had significantly lower likelihood of opioid/stimulant use than WLWH in the most SDoH adversities class. Compared with the most SDoH adversities class, weighted analysis showed that WLWH in no/least SDoH class were at decreased risk of drug use (RR = 0.13, 95% CI = 0.03, 0.58), while an association was not observed for other classes. Additionally, WLWH in the no/least SDoH class were at decreased risk of drug use compared to WLWH in the economic hardship class (RR = 0.13, 95% CI = 0.03, 0.63) and discrimination/stigma class (RR = 0.15; 95% CI = 0.03, 0.78) (Table 3).

The sensitivity analysis suggested that these associations were relatively robust to potential unmeasured confounding. For instance, for the observed RR = 0.13 for drug use among those with no/least SDoH adversities versus those with most adversities, an unmeasured confounder correlated with both exposure and outcome by RRs of ~14.86-fold each, above and beyond the measured confounders, would explain away the observed association, but weaker confounding would not. Such an E-value for

Table 2 Characteristics of women living with HIV (WLWH) across the Social Determinants of Health (SDoH) Classes—CHIWOS time-point 1, 2013–15 (*n* = 1422).

Variables	Overall	SDoH classes				P-value ^a
		None/least adversities	Discrimination/stigma	Economic hardship	Most adversities	
Age, years ^b [mean (SD)]	42.8 (10.6)	39.2 (10.3)	43.5 (10.6)	42.9 (11.5)	43.1 (10.0)	0.007
Ethno-racial group						< 0.001
White/Caucasian	584 (41.1) ^c	58 (61.7)	97 (37.9)	219 (50.9)	210 (32.7)	
African/Caribbean/black	418 (29.4)	23 (24.5)	109 (42.6)	123 (28.6)	163 (25.4)	
Indigenous	318 (22.3)	7 (7.4)	29 (11.3)	60 (14.0)	222 (34.6)	
Other	102 (7.2)	6 (6.4)	21 (8.2)	28 (6.5)	47 (7.3)	
Province						< 0.001
Ontario	717 (50.4)	50 (53.2)	131 (51.2)	235 (54.6)	301 (46.9)	
British Columbia	356 (25.0)	13 (13.8)	49 (19.1)	65 (15.1)	229 (35.7)	
Quebec	349 (24.6)	31 (33.0)	76 (29.7)	130 (30.2)	112 (17.5)	
Living in large cities	1169 (82.2)	83 (88.3)	203 (79.3)	345 (80.2)	538 (83.8)	0.106
Bing heterosexual	1237 (87.3)	85 (90.4)	237 (93.3)	395 (91.9)	520 (81.4)	< 0.001
Relationship status						< 0.001
Single (non-married)	689 (48.5)	40 (42.6)	100 (39.1)	201 (46.7)	348 (54.4)	
Married/common-law	454 (32.0)	44 (46.8)	103 (40.2)	134 (31.1)	173 (27.0)	
Others	277 (19.5)	10 (10.6)	53 (20.7)	95 (22.1)	119 (18.6)	
Years living with HIV						0.001
< 6 years	345 (25.1)	23 (25.0)	40 (15.7)	128 (31.4)	154 (24.8)	
6–14 years	552 (40.2)	35 (38.0)	118 (46.7)	140 (34.3)	259 (41.8)	
> 14 years	477 (34.7)	34 (37.0)	96 (37.8)	140 (34.3)	207 (33.4)	
Taking HIV treatment						0.001
Yes, optimal (≥ 95%)	863 (70.0)	65 (69.9)	163 (64.7)	279 (65.0)	356 (55.5)	
Yes, suboptimal (< 95%)	312 (22.0)	12 (12.9)	52 (21.4)	74 (17.2)	172 (26.8)	
Not engaged in treatment	240 (17.0)	16 (17.2)	35 (13.9)	76 (17.7)	113 (17.6)	
Mental health diagnosis	573 (40.7)	26 (28.0)	93 (36.6)	134 (31.6)	320 (50.3)	< 0.001
Resiliency (below median) ^d	662 (47.1)	22 (23.66)	104 (40.9)	172 (40.6)	364 (57.4)	< 0.001
Childhood violence	819 (62.7)	34 (38.6)	138 (56.8)	211 (53.8)	436 (74.7)	< 0.001
Adulthood violence	1057 (80.4)	52 (59.1)	189 (77.5)	284 (71.9)	532 (90.5)	< 0.001
Child development events	326 (23.0)	10 (10.6)	33 (13.0)	74 (17.3)	209 (32.7)	< 0.001
Heavy alcohol use						0.132
Abstainers/low (< 1 drink/week)	956 (69.1)	64 (68.8)	174 (68.5)	302 (71.1)	419 (68.1)	
Moderate (1–7 drinks/week)	288 (20.8)	22 (23.7)	60 (23.6)	88 (20.7)	118 (19.2)	
Heavy (> 7 drinks/week)	140 (10.1)	7 (7.5)	20 (7.9)	35 (8.2)	78 (12.7)	
Drug use history ^b						
Before study entry	234 (16.8)	3 (3.2)	10 (3.9)	48 (11.24)	173 (27.5)	< 0.001
At entry (time-point 1)	244 (17.5)	2 (2.2)	11 (4.3)	50 (11.9)	181 (28.8)	< 0.001

^aP-values are for the χ^2 test for categorical covariates and one-way analysis of variance (ANOVA) for continuous covariates; ^bopioid/stimulant use histories before and at time-point 1; ^cdata are presented as *n* (%) unless specified; ^dscores ranged from 10 to 70, with higher scores indicating increased resilience (median = 64). CHIWOS = Canadian HIV Women's Sexual and Reproductive Health Cohort Study; SD = standard deviation.

the upper 95% limit of the same association was 2.84-fold (Table 3).

DISCUSSION

In our study of data from a large prospective cohort of WLWH in Canada, we observed that most WLWH reported

experiencing multiple forms of a set of mutually reinforcing SDoH. We identified two partially overlapped SDoH clusters of discrimination/stigma and economic hardship as well as one cluster containing most of the SDoH adversities. Most notably, we found that the prevalence of self-reported opioid/stimulant use was approximately seven times higher in WLWH who experienced the most SDoH




Figure 1 Prevalence of drug use^a According to the Social Determinants of Health (SDoH) Classes Obtained from the Latent Class Analysis (LCA) —CHIWOS^b. ^aStimulants: cocaine, crack (crack cocaine), crystal, speed (amphetamine) and 3,4-methylenedioxymphetamine (MDA); opioids: heroin, speedballs (heroin + cocaine), Dilaudid (hydromorphone), non-prescription use of methadone, OxyContin/Oxycodone, morphine, Talwins and Ritalin. These drugs were measured at baseline (time-point 1, 2013–15) and in ~18-month follow-up (time-point 2; 2015–17); ^banalytical sample size for these prevalences was 1395 at time-point 1 and 1236 at time-point 2

adversities than those experiencing no/least adversity (26.4 versus 3.5%). WLWH with no/least adversity were substantially less likely to report drug use at ~18 months follow-up compared with WLWH experiencing an accumulation of social disadvantages.

Overall, the high prevalence of socio-structural adversities among WLWH is consistent with existing knowledge that women experience substantial SDoH vulnerabilities

and multiple forms of these adversities [52,53]. The majority of the SDoH indicators were well-distinguished across the SDoH classes using LCA analysis, except for low education, unstable housing, sex work involvement and incarceration. That these four determinants were less distinctive may be due to their relatively low proportions, and probably resulted in a low overall impact on drug use in the current sample of WLWH.

Table 3 Inverse probability weighted estimates of the association of the Social Determinants of Health (SDoH) classes with drug use among Women Living with HIV (WLWH)—CHIWOS.^a

SDoH classes ^b	Observed estimates				E-value for the observed estimates ^b	
	Crude RR ^c (95% CI)	P-value	Weighted RR (95% CI)	P-value	Weighted RR	Upper CI
Economic hardship class versus most SDoH adversities	0.53 (0.40, 0.71)	< 0.001	0.95 (0.67, 1.34)	0.760	–	–
Discrimination/stigma class versus most SDoH adversities	0.21 (0.12, 0.37)	< 0.001	0.82 (0.44, 1.52)	0.539	–	–
None/least adversities class versus most SDoH adversities	0.13 (0.04, 0.40)	< 0.001	0.13 (0.03, 0.58)	0.008	14.86	2.84
Discrimination/stigma class versus Economic hardship	0.40 (0.22, 0.71)	0.002	0.87 (0.44, 1.68)	0.678	–	–
None/least adversities class versus Economic hardship	0.24 (0.07, 0.76)	0.015	0.13 (0.03, 0.63)	0.011	14.86	2.55
None/least adversities class versus Discrimination/stigma	0.61 (0.18, 2.1)	0.440	0.15 (0.03, 0.78)	0.024	11.81	1.88

^an = 1236 in crude analysis and n = 1225 in weighted analysis; ^bthis is a sensitivity analysis evaluating the extent to which an unmeasured confounder would explain away the exposure-outcome estimates observed for the association between the SDoH classes and drug use. E-value was checked for the observed point estimate and the upper 95% CI that is close to the null RR = 1. ^cRR: risk ratio [95% confidence intervals (CI)]; CHIWOS = Canadian HIV Women’s Sexual and Reproductive Health Cohort Study.

We documented that the clustered classes of multiple SDoH adversities were associated with drug use. Notably, no difference was observed in the risk of drug use for the two classes of discriminations/stigma and economic hardship compared with the class with most SDoH adversities and also the same risk of drug use was estimated when WLWH in the no/least class were compared with WLWH in these two classes. Such findings may help to shed light on the processes that generate and reinforce well-documented syndemics of HIV and substance use by showing the role that each specific cluster of SDoH may play in initiation/continuation of drug use. Our results suggest that improving modifiable social determinants may be crucial to addressing this syndemic [54]. Harm reduction and treatment interventions need to seriously consider the important role of multiple SDoH—regardless of their types. Drug treatment programs that mainly focus on behavior change interventions may result in limited impact if no additional efforts are made to change the social environments of drug users [55].

Our findings may also have implications for HIV care and treatment programs by illuminating the association of current social determinants with illicit drug use, which has been shown to create challenges within the HIV care cascade. Prior evidence has demonstrated how income level [56], HIV stigma [22] and food insecurity [57] increase vulnerabilities to suboptimal cART adherence by limiting access to HIV care and treatment services, and affecting individuals' health-seeking behaviors. Illicit drug use, e.g. crack cocaine, also impacts HIV clinical care through the same mechanism of HIV treatment interruptions [2,10,11,58]. Individually or combined, these factors can threaten the benefits accompanied with early HIV treatment initiation and the commitments toward eliminating the HIV pandemic. Paying particular attention to these interlinked social and drug use determinants should be a key priority in efforts to improve HIV medical care for WLWH, and merits continued and thorough investigation. Given the impacts of these SDoH adversities and risk practices on HIV care and treatment outcomes, these findings indicate a need for regular assessment of these factors and targeted support for women with greater needs within routine HIV care [59] which, if addressed holistically, may reduce the likelihood of suboptimal HIV clinical outcomes.

While this study took advantage of CHIWOS as the largest community-based research cohort of WLWH in Canada, it had some limitations. First, non-random sampling of the participants may limit the generalizability and interpretation of our findings. Secondly, we relied on self-reported drug use, which may be subject to social desirability bias; however, participants were interviewed by PRAs who also experienced living with HIV (and in some cases, using drugs), and this may have limited such bias. Thirdly, although unmeasured confounding is a source of

bias in observational research, our sensitivity analysis showed that relatively strong unmeasured confounding would be required to nullify the observed associations.

The current research has several strengths despite these limitations: first, we used data from a nation-wide large sample of WLWH. Secondly, our research extends the relatively limited extant knowledge on drug use among women with HIV. Thirdly, our research contributes to theoretical development through examining the inclusion of detailed individual-level data of current and modifiable social determinants as leading stressors in the target population's daily life. Fourthly, we demonstrated how these determinants cluster together using LCA, a probability-based technique that provides a better insight into the underlying clusters of the individual SDoH indicators given the concurrent occurrence of these determinants. Fifthly, IPW was used to account for both confounding and selection bias. Finally, the survey had a high retention rate (88%) after 18 months of follow-up.

Despite a growing body of evidence on the independent associations between social determinants and drug use, less focus has been put on ways these determinants overlap, or on their clustering impacts on drug use. The complex relationships between the SDoH indicators, the documented (individual) associations with barriers to care and stigma that surrounds both drug use and many aspects of social adversity suggest that HIV care programs will need to make intentional efforts to ensure that patients have full access to optimal care across the HIV care cascade. Our findings support the targeted assessment of multiple social determinant and drug use vulnerabilities; HIV-specific and women-centered care models have good potential to create the kind of low-stigma environment that would allow for these issues to be both assessed and addressed [60]. Developing evidence-based treatment for drug dependence, including harm reduction strategies, requires a recognition of the role of social determinants of health. Individuals with these socio-structural adversities in intersection with drug use may continue to experience greater challenges with regard to HIV treatment adherence and HIV outcomes; therefore, the continued support for individuals with greater vulnerabilities is required.

Declaration of interests

None.

Acknowledgements

CHIWOS is supported by funding from the Canadian Institutes of Health Research (CIHR (Grant no: MOP-111041; FDN154325); the CIHR Canadian HIV Trials Network (CTN 262); the Ontario HIV Treatment Network; and the Academic Health Science Centres (AHSC) Alternative Funding Plans (AFP) Innovation Fund.

Authors' affiliations

Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada,¹ Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada,² Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, Ontario, Canada,³ Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada,⁴ School of Social Work, University of Michigan, Ann Arbor, Michigan, USA,⁵ British Columbia Centre on Substance Use, St. Paul's Hospital, Vancouver, BC, Canada,⁶ Department of Medicine, University of British Columbia, Vancouver, BC, Canada,⁷ Vancouver Coastal Health, Vancouver, British Columbia, Canada,⁸ Epidemiology and Population Health Program, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada,⁹ Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada¹⁰ and Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada¹¹

*The CHIWOS Research Team: Rahma Abdul-Noor (Women's College Research Institute), Aranka Anema (University of British Columbia), Jonathan Angel (Ottawa Hospital Research Institute), Jean-Guy Baril (Clinique du Quartier Latin), Fatimatou Barry (Women's College Research Institute), Kerrigan Beaver (Women's College Research Institute), Denise Becker (Positive Living Society of British Columbia), Anita Benoit (Women's College Research Institute), Jason Brophy (Children's Hospital of Eastern Ontario), Lori Brotto (University of British Columbia), Ann Burchell (Ontario HIV Treatment Network), Claudette Cardinal (Simon Fraser University), Allison Carlson (Women's College Research Institute), Allison Carter (British Columbia Centre for Excellence in HIV/AIDS and Simon Fraser University), Angela Cescon (British Columbia Centre for Excellence in HIV/AIDS), Lynne Cioppa (Women's College Research Institute), Jeffrey Cohen (Windsor Regional Hospital), Guillaume Colley (British Columbia Centre for Excellence in HIV/AIDS), Tracey Conway (Women's College Research Institute), Curtis Cooper (Ottawa Hospital Research Institute), Jasmine Cotnam (Women's College Research Institute), Janette Cousineau (Women's College Research Institute), Janice Dayle (McGill University Health Centre), Marisol Desbiens (Women's College Research Institute), Hania Dubinsky (McGill University Health Centre), Danièle Dubuc (McGill University Health Centre), Janice Duddy (Pacific AIDS Network), Brenda Gagnier (Women's College Research Institute), Jacqueline Gahagan (Dalhousie University), Claudine Gasingirwa (Women's College Research Institute), Nada Gataric (British Columbia Centre for Excellence in HIV/AIDS), Saara Greene (McMaster University), Trevor Hart (Ryerson University), Catherine Hankins (UNAIDS), Bob Hogg (British Columbia Centre for Excellence in HIV/AIDS and Simon Fraser University), Terry Howard (Positive Living Society of British Columbia), Shazia Islam (Women's College Research Institute), Evin Jones (Pacific AIDS Network), Charu Kaushic (McMaster University), Alexandria Keating (VIVA and Southern Gulf Islands AIDS Society), Logan Kennedy (Women's College Research Institute), Mary Kestler (Oak Tree Clinic, BC Women's Hospital and Health Centre), Maxime Kiboyogo (McGill University Health Centre), Marina Klein (McGill University Health Centre), Gladys Kwaramba (Women's College Research Institute), Andrea Langlois (Pacific AIDS Network), Melanie Lee (Simon Fraser University), Rebecca Lee (CIHR Canadian HIV Trials Network), Lynne Leonard (University of Ottawa), Johanna Lewis (Women's College Research Institute), Viviane Lima (British Columbia Centre for Excellence in HIV/AIDS), Elisa Lloyd-Smith (Vancouver Coastal Health), Carmen Logie (University of Toronto), Shari Margolese (Women's College Research Institute), Carrie Martin (Native Women's Shelter of Montreal), Renee Masching (Canadian Aboriginal AIDS Network), Lyne Massie (Université du Québec à Montréal), Melissa Medjuck (Positive Women's Network), Brigitte Ménard, (McGill University Health Centre), Cari Miller (Simon Fraser University), Deborah Money (Women's Health Research Institute), Marvelous Muchenje (Women's Health in Women's Hands), Mary Mwalwanda (Women's College Research Institute), Mary (Muthoni) Ndung'u (Women's College Research Institute), Valerie Nicholson (Simon Fraser University), Illuminée Nzikwikiza (McGill University Health Centre), Kelly O'Brien (University of Toronto), Nadia O'Brien (McGill University Health Centre and McGill University), Gina Ogilvie (British Columbia Centre for Disease Control), Susanna Ogunnaiké-Cooke (Public Health Agency of Canada), Joanne Otis (Université du Québec à Montréal), Ali Palmer (Simon Fraser University), Sophie Patterson (Simon Fraser University), Doris Peltier (Canadian Aboriginal AIDS Network), Yasmeen (Ashria) Persad (Women's College Research Institute), Neora Pick (Oak Tree Clinic, BC Women's Hospital and Health Centre), Alie Pierre,

McGill University Health Centre), Jeff Powis (Toronto East General Hospital), Karène Proulx-Boucher (McGill University Health Centre), Corinna Quan (Windsor Regional Hospital), Janet Raboud (Ontario HIV Treatment Network), Anita Rachlis (Sunnybrook Health Science Centre), Edward Ralph (St Joseph's Health Care), Stephanie Rawson, (Simon Fraser University, BC), Eric Roth (University of Victoria), Danielle Rouleau (Centre Hospitalier de l'Université de Montréal), Sean Rourke (Ontario HIV Treatment Network), Sergio Rueda (Centre for Addiction and Mental Health), Mercy Saavedra (Women's College Research Institute), Kate Salters (Simon Fraser University), Margarite Sanchez (VIVA and Southern Gulf Islands AIDS Society), Roger Sandre (Haven Clinic), Jacque Sas (CIHR Canadian HIV Trials Network), Paul Sereda (British Columbia Centre for Excellence in HIV/AIDS), Fiona Smail (McMaster University), Stephanie Smith (Women's College Research Institute), Marcie Summers (Positive Women's Network), Tsitsi Tigere (Women's College Research Institute), Wangari Tharao (Women's Health in Women's Hands), Jamie Thomas-Pavanel (Women's College Research Institute), Christina Tom (Simon Fraser University, BC), Cécile Tremblay (Centre Hospitalier de l'Université de Montréal), Benoit Trotter (Clinique l'Actuel), Sylvie Trotter (Centre Hospitalier Universitaire de Québec), Christos Tsoukas (McGill University Health Centre), Anne Wagner (Ryerson University), Sharon Walmsley (Toronto General Research Institute), Kath Webster (Simon Fraser University), Wendy Wobeser (Kingston University), Jessica Yee (Native Youth Sexual Health Network), Mark Yudin (St-Michael's Hospital) and Wendy Zhang (British Columbia Centre for Excellence in HIV/AIDS). All other CHIWOS Research Team Members who wish to remain anonymous.

References

1. Cohn S. E., Jiang H., McCutchan J. A., Koletar S. L., Murphy R. L. *et al.* Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. *AIDS Care* 2011; **23**: 775–85.
2. Cook J. A., Burke-Miller J. K., Cohen M. H., Cook R. L., Vlahov D., Wilson T. E. *et al.* Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. *AIDS* 2008; **22**: 1355–63.
3. Shokoohi M., Bauer G. R., Kaida A., Lacombe-Duncan A., Kazemi M., Gagnier B. *et al.* Substance use patterns among women living with HIV compared with the general female population of Canada. *Drug Alcohol Depend* 2018; **191**: 70–7.
4. Lima V. D., Harrigan R., Bangsberg D. R., Hogg R. S., Gross R., Yip B. *et al.* The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. *J Acquir Immune Defic Syndr* 2009; **50**: 529–36.
5. Gonzalez A., Mimiaga M. J., Israel J., Andres Bedoya C., Safren S. A. Substance use predictors of poor medication adherence: the role of substance use coping among HIV-infected patients in opioid dependence treatment. *AIDS Behav* 2013; **17**: 168–73.
6. Kerkerian G., Kestler M., Carter A., Wang L., Kronfli N., Sereda P. *et al.* Attrition across the HIV cascade of care among a diverse cohort of women living with HIV in Canada. *J Acquir Immune Defic Syndr* 2018; **79**: 226–36.
7. Puskas C. M., Kaida A., Miller C. L., Zhang W., Yip B., Pick N. *et al.* The adherence gap: a longitudinal examination of men's and women's antiretroviral therapy adherence in British Columbia, 2000–2014. *AIDS* 2017; **31**: 827–33.
8. Cescon A., Patterson S., Chan K., Palmer A. K., Margolese S., Burchell A. N. *et al.* Gender differences in clinical outcomes among HIV-positive individuals on antiretroviral therapy in Canada: a multisite cohort study. *PLOS ONE* 2013; **8**: e83649.
9. Hogg R. S., Eyawo O., Collins A. B., Zhang W., Jabbari S., Hull M. W. *et al.* Health-adjusted life expectancy in HIV-positive

- and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study. *Lancet HIV* 2017; 4: e270–e276.
10. Kapadia F, Cook J. A., Cohen M. H., Sohler N., Kovacs A., Greenblatt R. M. *et al.* The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use. *Addiction* 2005; 100: 990–1002.
 11. Zhang Y., Wilson T. E., Adedimeji A., Merenstein D., Milam J., Cohen J. *et al.* The impact of substance use on adherence to antiretroviral therapy among HIV-infected women in the United States. *AIDS Behav* 2018; 22: 896–908.
 12. Petoumenos K., Law M. G. Smoking, alcohol and illicit drug use effects on survival in HIV-positive persons. *Curr Opin HIV AIDS* 2016; 11: 514–20.
 13. Malta M., Strathdee S. A., Magnanini M. M., Bastos F. I. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. *Addiction* 2008; 103: 1242–57.
 14. Milloy M. J., Montaner J., Wood E. Barriers to HIV treatment among people who use injection drugs: implications for 'treatment as prevention'. *Curr Opin HIV AIDS* 2012; 7: 332–8.
 15. Dingle G. A., Cruwys T., Frings D. Social identities as pathways into and out of addiction. *Front Psychol* 2015; 6: 1795.
 16. Commission on Social Determinants of Health. Closing the Gap in a Generation: Health Equity Through Action on the Social Determinants of Health. Geneva: World Health Organization. Available at: http://www.who.int/social_determinants/thecommission/finalreport/en/ (accessed 4 January 2019) (Archived at <http://www.webcitation.org/75B511X90> on 4 January 2019).
 17. Logie C. H., James L., Tharao W., Loutfy M. R. HIV, gender, race, sexual orientation, and sex work: a qualitative study of intersectional stigma experienced by HIV-positive women in Ontario, Canada. *PLOS Med* 2011; 8: e1001124.
 18. Turan B., Hatcher A. M., Weiser S. D., Johnson M. O., Rice W. S., Turan J. M. Framing mechanisms linking HIV-related stigma, adherence to treatment, and health outcomes. *Am J Public Health* 2017; 107: 863–9.
 19. Mikkonen J., Raphael D. Social determinants of health: the Canadian facts. Toronto: York University School of Health Policy and Management. Available at: <http://thecanadianfacts.org/> (accessed 4 January 2019) (Archived at <http://www.webcitation.org/75B4PhDnv> on 4 January 2019).
 20. Azim T., Bontell I., Strathdee S. A. Women, drugs and HIV. *Int J Drug Policy* 2015; 26: S16–S21.
 21. Johnson M., Samarina A., Xi H., Valdez Ramalho Madruga J., Hocqueloux L., Loutfy M. *et al.* Barriers to access to care reported by women living with HIV across 27 countries. *AIDS Care* 2015; 27: 1220–30.
 22. Rueda S., Mitra S., Chen S., Gogolishvili D., Globerman J., Chambers L. *et al.* Examining the associations between HIV-related stigma and health outcomes in people living with HIV/AIDS: a series of meta-analyses. *BMJ Open* 2016; 6: e011453.
 23. Edelman E. J., Lunze K., Cheng D. M., Lioznov D. A., Quinn E., Gnatenko N. *et al.* HIV stigma and substance use among HIV-positive Russians with risky drinking. *AIDS Behav* 2017; 21: 2618–27.
 24. Palar K., Laraia B., Tsai A. C., Johnson M. O., Weiser S. D. Food insecurity is associated with HIV, sexually transmitted infections and drug use among men in the United States. *AIDS* 2016; 30: 1457–65.
 25. Gamarel K. E., Brown L., Kahler C. W., Fernandez M. I., Bruce D., Nichols S. Prevalence and correlates of substance use among youth living with HIV in clinical settings. *Drug Alcohol Depend* 2016; 169: 11–8.
 26. Skalski L. M., Sikkema K. J., Heckman T. G., Meade C. S. Coping styles and illicit drug use in older adults with HIV/AIDS. *Psychol Addict Behav* 2013; 27: 1050–8.
 27. Loutfy M., de Pokomandy A., Kennedy V. L., Carter A., O'Brien N., Proulx-Boucher K. *et al.* Cohort profile: the Canadian HIV Women's Sexual and Reproductive Health Cohort Study (CHIWOS). *PLOS ONE* 2017; 12: e0184708.
 28. Lanza S. T., Rhoades B. L. Latent class analysis: an alternative perspective on subgroup analysis in prevention and treatment. *Prev Sci* 2013; 14: 157–68.
 29. Jones A. A., Gerke T., Striley C. W., Whitehead N., Osborne V., Cottler L. B. One step at a time: a latent transitional analysis on changes in substance use, exposure to violence, and HIV/AIDS risk behaviors among female offenders. *Am J Crim Justice* 2018; 43: 471–85.
 30. Webster K., Carter A., Proulx-Boucher K., Dubuc D., Nicholson V., Beaver K. *et al.* Strategies for recruiting women living with human immunodeficiency virus in community-based research: lessons from Canada. *Prog Community Health Partnersh* 2018; 12: 21–34.
 31. VanderWeele T. J., Robinson W. R. On the causal interpretation of race in regressions adjusting for confounding and mediating variables. *Epidemiology* 2014; 25: 473–84.
 32. Williams D. R., Yan Y., Jackson J. S., Anderson N. B. Racial differences in physical and mental health: socio-economic status, stress and discrimination. *J Health Psychol* 1997; 2: 335–51.
 33. McLaughlin K. A., Hatzenbuehler M. L., Keyes K. M. Responses to discrimination and psychiatric disorders among Black, Hispanic, female, and lesbian, gay, and bisexual individuals. *Am J Public Health* 2010; 100: 1477–84.
 34. Wright K., Naar-King S., Lam P., Templin T., Frey M. Stigma scale revised: reliability and validity of a brief measure of stigma for HIV+ youth. *J Adolesc Health* 2007; 40: 96–8.
 35. Gjesfeld C. D., Greeno C. G., Kim K. H. A confirmatory factor analysis of an abbreviated social support instrument: the MOS-SSS. *Res Soc Work Pract* 2008; 18: 231–7.
 36. McCoy S. I., Strauss R. P., MacDonald P. D., Leone P. A., Eron J. J., Miller W. C. Social support and delays seeking care after HIV diagnosis, North Carolina, 2000–2006. *AIDS Care* 2009; 21: 1148–56.
 37. Heckman T. G., Somlai A. M., Peters J., Walker J., Otto-Salaj L., Galdabini C. A. *et al.* Barriers to care among persons living with HIV/AIDS in urban and rural areas. *AIDS Care* 1998; 10: 365–75.
 38. Vozoris N. T., Tarasuk V. S. Household food insufficiency is associated with poorer health. *J Nutr* 2003; 133: 120–6.
 39. Wagnild G. A review of the Resilience Scale. *J Nurs Meas* 2009; 17: 105–13.
 40. Howards P. P., Schisterman E. E., Heagerty P. J. Potential confounding by exposure history and prior outcomes: an example from perinatal epidemiology. *Epidemiology* 2007; 18: 544–51.
 41. Groenwold R. H., White I. R., Donders A. R., Carpenter J. R., Altman D. G., Moons K. G. Missing covariate data in clinical research: when and when not to use the missing-indicator method for analysis. *Can Med Assoc J* 2012; 184: 1265–9.

42. Dempster A. P., Laird N. M., Rubin D. B. Maximum likelihood from incomplete data via the EM algorithm. *J R Stat Soc Series B Stat Methodol* 1977; **39**: 1–38.
43. Akaike H. Factor analysis and AIC. *Psychometrika* 1987; **52**: 317–32.
44. Schwartz G. Estimating the dimension of a model. *Ann Stat* 1987; **6**: 461–4.
45. Sclove L. Application of model-selection criteria to some problems in multivariate analysis. *Psychometrika* 1987; **52**: 333–43.
46. Celeux G., Soromenho G. An entropy criterion for assessing the number of clusters in a mixture model. *J Classif* 1996; **13**: 195–212.
47. Lanza S. T., Dziak J. J., Huang L., Xu S., Collins L. M. PROC LCA and PROC LTA User's Guide. State College, University Park, PA: The Methodology Center, Pennsylvania State University; 2015.
48. Hernan M., Robbins J. IP Weighting and Marginal Structural Models in Causal Inference. Boca Raton: Chapman & Hall/CRC. Available at: <https://www.hsph.harvard.edu/miguel-hernan/causal-inference-book/> (accessed 4 January 2019) (Archived at <http://www.webcitation.org/75B3ozbot> on 4 January 2019).
49. Hernan M. A., Brumback B., Robins J. M. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. *Epidemiology* 2000; **11**: 561–70.
50. Cole S. R., Hernan M. A. Constructing inverse probability weights for marginal structural models. *Am J Epidemiol* 2008; **168**: 656–64.
51. VanderWeele T. J., Ding P. Sensitivity analysis in observational research: introducing the E-Value. *Ann Intern Med* 2017; **167**: 268–74.
52. Higgins J. A., Hoffman S., Dworkin S. L. Rethinking gender, heterosexual men, and women's vulnerability to HIV/AIDS. *Am J Public Health* 2010; **100**: 435–45.
53. Logie C. H., Wang Y., Marcus N., Kaida A., O'Brien N., Nicholson V. *et al.* Factors associated with the separate and concurrent experiences of food and housing insecurity among women living with HIV in Canada. *AIDS Behav* 2018; **22**: 3100–10.
54. Singer M., Clair S. Syndemics and public health: reconceptualizing disease in bio-social context. *Med Anthropol Q* 2003; **17**: 423–41.
55. Spooner C., Hetherington K. Social determinants of drug use. Sydney, National Drug and Alcohol Research Centre: University of New South Wales; 2005.
56. McFall A. M., Dowdy D. W., Zelaya C. E., Murphy K., Wilson T. E., Young M. A. *et al.* Understanding the disparity: predictors of virologic failure in women using highly active antiretroviral therapy vary by race and/or ethnicity. *J Acquir Immune Defic Syndr* 2013; **64**: 289–98.
57. Singer A. W., Weiser S. D., McCoy S. I. Does food insecurity undermine adherence to antiretroviral therapy? A systematic review. *AIDS Behav* 2015; **19**: 1510–26.
58. Baum M. K., Rafie C., Lai S., Sales S., Page B., Campa A. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. *J Acquir Immune Defic Syndr* 2009; **50**: 93–9.
59. Korthuis P. T., Josephs J. S., Fleishman J. A., Hellinger J., Himelhoch S., Chander G. *et al.* Substance abuse treatment in human immunodeficiency virus: the role of patient-provider discussions. *J Subst Abuse Treat* 2008; **35**: 294–303.
60. Carter A. J., Bourgeois S., O'Brien N., Abelsohn K., Tharao W., Greene S. *et al.* Women-specific HIV/AIDS services: identifying and defining the components of holistic service delivery for women living with HIV/AIDS. *J Int AIDS Soc* 2013; **16**: 17433.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1 Comparison of Goodness-of-fit Measures for Different Class Models ($N = 1422$).

Table S2 Characteristics of Women Living with HIV (WLWH) Who Were Lost to Follow-up (i.e., censored), CHIWOS, 2013–2017.

Table S3 Distributions of the Estimated Weights for the Classes of the Social Determinants of Health (SDoH), Censoring, and Both, CHIWOS, time-point 1, 2013–2015.

Table S4 Inverse-Probability Weighted Estimates of the Parameters of a Marginal Structural Model for the Association of the Classes of the Social Determinants of Health (SDoH) on Drug Use among Women Living with HIV (WLWH), CHIWOS, Canada, 2013–2017.